{
    "nct_id": "NCT04835584",
    "official_title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor (TKI) in Patients With Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)",
    "inclusion_criteria": "* Phase 1b and Phase 2 Arms A and B: Documented TP53wt, Ph+, BCR-ABL+ CML-CP\n* Phase 2 Arm C ONLY: Documented TP53wt, Ph+, BCR-ABL+ CML-AP\n* Subject is resistant (relapsed or refractory) and/or intolerant to at least 1 prior TKI.\n* Adults â‰¥ 18 years of age.\n* ECOG performance status of 0 to 2\n* Adequate hematologic, hepatic, and renal functions\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Phase 1b and Phase 2 Arms A and B: Documented Ph+, BCR-ABL+ CML-AP\n* Documented Ph+, BCR-ABL+ CML-BC\n* Known T315I mutation.\n* Prior treatment with MDM2 antagonist therapies.\n* Intolerance to current TKI therapy.",
    "miscellaneous_criteria": ""
}